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Background: Dronedarone has been developed for treatment of atrial fibrillation (AF) or atrial 
flutter (AFL). It is an amiodarone analogue but noniodinized and without the same adverse 
effects as amiodarone.
Objective and methods: This is a review of 7 studies (DAFNE, ADONIS, EURIDIS, 
ATHENA, ANDROMEDA, ERATO and DIONYSOS) on dronedarone focusing on efficacy, 
safety and prevention of stroke. There was a dose-finding study (DAFNE), 3 studies focusing 
on maintenance of sinus rhythm (ADONIS, EURIDIS and DIONYSOS), 1 study focusing on 
rate control (ERATO) and 2 studies investigating mortality and morbidity (ANDROMEDA 
and ATHENA).
Results: The target dose for dronedarone was established in the DAFNE study to be 400 mg 
twice daily. Both EURIDIS and ADONIS studies demonstrated that dronedarone was superior 
to placebo for maintaining sinus rhythm. However, DIONYSOS found that dronedarone is less 
efficient at maintaining sinus rhythm than amiodarone. ERATO concluded that dronedarone 
reduces ventricular rate in patients with chronic AF. The ANDROMEDA study in patients with 
severe heart failure was discontinued because of increased mortality in dronedarone group. 
Dronedarone reduced cardiovascular hospitalizations and mortality in patients with AF or AFL 
in the ATHENA trial. Secondly, according to a post hoc analysis a significant reduction in stroke 
was observed (annual rate 1.2% on dronedarone vs 1.8% on placebo, respectively [hazard ratio 
0.66, confidence interval 0.46 to 0.96, P = 0.027]). In total, 54 cases of stroke occurred in 3439 
patients (crude rate 1.6%) receiving dronedarone compared to 76 strokes in 3048 patients on 
placebo (crude rate 2.5%), respectively.
Conclusion: Dronedarone can be used for maintenance of sinus rhythm and can reduce stroke 
in patients with AF who receive usual care, which includes antithrombotic therapy and heart 
rate control.
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The risk of stroke in patients with atrial fibrillation
Stroke associated with atrial fibrillation (AF) is often disabling and life threatening. 
Stroke is the second most common cause of death after ischemic heart disease in the 
world with 4.38 million deaths in developed countries and almost 3 million in developing 
countries.1 Stroke causes 10% to 12% of deaths in industrialized countries. Almost 90% 
of deaths caused by stroke occur in people over 65 years of age.2 The Framingham study 
showed that AF is an independent risk factor for development of stroke, particularly in 
the elderly.3 Given that AF is a known risk factor for stroke, it seems appealing that a 
drug with antiarrhythmic effect can reduce the incidence of stroke in patients with AF. Clinical Interventions in Aging 2010:5 64
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However, previous studies point in the opposite direction: 
Rhythm Control versus Rate Control for Atrial Fibrillation 
and Heart Failure, Atrial Fibrillation Follow-up Investigation 
of Rhythm Management (AFFIRM) showed that antiarrhyth-
mic drugs reduced the recurrence of AF, but did not show 
any reduction in stroke.4 In a meta-analysis of randomized 
trials of rate vs rhythm control for AF from 2005 there was 
an insignificant increase in stroke in the group of patients 
who received rhythm control.5 The incidence of stroke has 
declined due to treatment with oral anticoagulant therapy, and 
is around 1.4%/year in patients with AF.6,7 However, AF is 
often associated with advanced age and concomitant disease 
that disposes to stroke: hypertension, hypercholesterolemia, 
diabetes and heart failure. Prevention of stroke may require 
treatment of several conditions in order to become effective. 
Thus, it may not be surprising that antiarrhythmic therapy have 
not been able to prevent stroke in randomized clinical trials.
Dronedarone, a new antiarrhythmic  
drug
Dronedarone has been developed by Sanofi-Aventis for 
treatment of AF or atrial flutter (AFL). Dronedarone is a 
benzofuran derivative and primarily a class III antiarrhythmic 
drug but with properties from all four classes of the 
Vaughan-Williams classification. It is an amiodarone analogue 
but noniodinized and without many of the adverse effects 
associated with amiodarone. It has antiadrenergic properties 
and inhibits multiple transmembrane potassium currents, 
including the delayed rectifier current (both the rapid and slow 
components (IKr and IKs, respectively), the ultrarapid rectifier 
current (Ikur), the inward rectifier current (IK1), and the 
transient outward current (ITo), as well as sodium and L-type 
calcium currents.8,9 Dronedarone is approximately 100 times 
more potent than amiodarone and sotalol on the acetylcholine 
receptor-operated K+ current which is important when vagal 
tone plays a role in the genesis of AF.10 The removal of iodine 
is thought to be the reason for the lack of typical amiodarone 
side effects such as discoloration of skin, and affects on of lung, 
liver, and thyroid gland. Dronedarone is less lipophilic and has 
a much shorter half-life than amiodarone because of a methyl-
sulfonamide group. Dronedarone interferes with the metabo-
lism of digoxin, but not with the metabolism of warfarin.11 It 
is hepatically metabolized and excreted with feces.
Clinical effects of dronedarone
There are 7 important studies with dronedarone, of which 
two were powered to show effects on mortality and 
morbidity.
The DAFNE trial (dronedarone Atrial Fibrillation study 
after Electrical Cardioversion) studied the most appropriate 
dose of dronedarone to maintain sinus rhythm after cardio-
version.12 The study included 199 patients with persistent 
AF. Patients with severe heart failure or left ventricular ejec-
tion fraction (LVEF)  35% were excluded. The patients 
were randomized to 4 different groups and received either 
placebo or dronedarone in doses of 400 mg, 600 mg or 
800 mg twice daily. DAFNE showed that the most appro-
priate dose of dronedarone was 400 mg twice daily for 
prevention of AF relapses in patients after cardioversion. 
It was somewhat puzzling that higher doses of dronedarone 
were less efficient than 400 mg twice daily. Multivariable 
adjustment for baseline characteristics resulted in identical 
results. The most likely explanation is that higher dosages 
were limited by adverse events resulting in discontinuation 
of the drug. There was no report of stroke in any of the 
dronedarone groups or in the placebo group. There was one 
case of thrombosis (1.3%) in the group that received 800 mg 
twice daily and none in the other groups.
EURIDIS (European Trial in AF or AFL Patients receiv-
ing dronedarone for the Maintenance of Sinus Rhythm) 
and ADONIS (American-Australian-African Trial with 
dronedarone in AF or AFL Patients for the Maintenance of 
Sinus Rhythm) were two identical studies of which one was 
European and one non-European.13 All included patients had 
a history of AF but did not have AF at the time of enrolment. 
The purpose of the studies was to prevent recurrence of AF 
with dronedarone (n = 828) compared to placebo (n = 409). 
In both EURIDIS and ADONIS dronedarone increased 
the time to recurrence of AF significantly compared to the 
placebo: 96 days in 41 days (P value = 0.01) and 158 days 
vs 59 days (P = 0.002), respectively. In the European trial 
67% of the patients had had a recurrence of AF vs 77.5% in 
the placebo group (hazard ratio [HR] 0.78, 95% confidence 
interval [CI] 0.64 to 0.96, P = 0.01). In the non-European 
trial 61.1% of patients in the dronedarone group had had a 
recurrence of AF vs 72.8% in the placebo group (HR 0.73, 
95% CI 0.59 to 0.89, P = 0.002).These high rates of recur-
rence of AF in EURIDIS and ADONIS could lead to the 
assumption that dronedarone is less efficient in maintaining 
sinus rhythm than other antiarrhythmic drugs. However, the 
populations of different studies vary considerably, which 
makes direct comparison impossible.
There was no significant difference in the number of 
strokes reported as there were 4 strokes (0.5%) in the 
dronedarone group and 3 strokes (0.7%) in the placebo 
group (P = 0.69). Stroke included cerebral-artery embolism, Clinical Interventions in Aging 2010:5 65
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cerebrovascular accident, cerebral infarction, and transient 
ischemic attack.
The efficacy and safety of dronedarone for the control 
of ventricular rate during AF (ERATO) study assessed the 
efficacy of dronedarone in the control of ventricular rate in 
patients with permanent AF.14 The study enrolled 85 patients 
in the dronedarone group receiving 400 mg dronedarone 
twice daily and 89 in the placebo group. All patients had 
a history of symptomatic, permanent AF for minimum 
6 months and resting ventricular rate of at least 80 beats 
per minute. ERATO demonstrated a highly significant rate 
reduction in patients with permanent AF. At day 14 the 
mean ventricular rate was measured to be 11.7 beats less in 
the dronedarone group than at day 0 (P  0.0001). During 
submaximal and maximal exercise the mean ventricular rate 
at day 14 was reduced by 25.6 and 27.4 beats, respectively, vs 
a 2.2 and 2.9 beats per minute reduction in the placebo group 
(both P  0.0001). There is no report of stroke in ERATO. 
The serious cardiovascular events included 3 myocardial 
infarctions (1 in dronedarone vs 2 in placebo group) and 1 
heart failure (in the dronedarone group) and 1 unstable angina 
(in the placebo group).14
A comparison of dronedarone and amiodarone was made 
in the efficacy and safety of dronedarone vs amiodarone 
for the maintenance of sinus rhythm in patients with 
AF (DIONYSOS) trial. The 504 patients scheduled for 
cardioversion for AF or AFL were randomized to amioda-
rone or dronedarone (400 mg twice daily), and the primary 
endpoint was the combined endpoint of recurrence of AF 
or premature discontinuation. DIONYSOS has not been 
published, but a press release (http://en.sanofi-aventis.com/
binaries/20081223_dionysos_fe_en_en_tcm28-23624.pdf) 
reveals that dronedarone has a higher rate of recurrence of 
AF or premature discontinuation after a year than amioda-
rone (HR approximately 1.6; P  0.01). Recurrence of AF 
occurred for 158 patients in the dronedarone group vs 107 
in the placebo group. The significant reduction in recurrence 
of AF by amiodarone is consistent with an indirect meta-
analysis based on 4 studies of amiodarone and 4 studies of 
dronedarone.15
Is dronedarone safe?
The antiarrhythmic trial with dronedarone in moderate to 
severe congestive heart failure evaluating morbidity decrease 
(ANDROMEDA) trial was a placebo-controlled multicenter 
study performed in patients admitted to hospital with 
moderate to severe heart failure and reduced left ventricular 
ejection fraction (LVEF).16 The study was performed in order 
to show a reduction in morbidity and mortality in patients 
with severe heart failure. The study was planned to include 
1000 patients and last for a minimum of 2 years. Every patient 
was treated for a minimum of 12 months. The primary end 
point was death from any cause or hospitalization for wors-
ening heart failure. Secondary end points included all cause 
mortality and hospitalization for cardiovascular causes. After 
inclusion of 627 patients (310 in the dronedarone group and 
317 in the placebo group), the study was discontinued, when 
the Data, Safety and Management Board (DSMB) found 
that dronedarone was associated with a significantly higher 
mortality. After a median 2-month follow-up, 25 patients in 
the dronedarone group and 12 patients in the control group 
had died, respectively. DSMB recommended that the study 
was stopped prematurely. Based on the small number of 
events it is difficult to know if this decision was correct. 
However, the increased mortality in the dronedarone was 
discovered at the first look at data, and repeated 1 month 
later. The steering committee discussed whether the advice 
of the DSMB should be followed, and decided to stop the 
study. Subgroup analyses could not identify a specific group 
of patients to which the increased risk was confined, but the 
risk seemed to be associated with the sickest patients. In the 
dronedarone group an increased number had an increase in 
serum creatinine. It was suggested that dronedarone might 
decrease renal function but this suggestion was later rejected. 
On the contrary, a study among 12 healthy males showed 
that dronedarone increases serum creatinine (increasing 
tubular secretion) without decreasing renal function.17 In 
ANDROMEDA, 4 (5.6%) in the dronedarone group and 
3 (6.0%) in the placebo group suffered from stroke requiring 
a first hospitalization.
As the population in ANDROMEDA consisted of 
patients with moderate to severe heart failure, a large study in 
patients of medium risk was planned following the results of 
ANDROMEDA. The study was done in patients with current 
or recent AF in order to show if dronedarone could affect 
mortality or morbidity. A placebo-controlled, double-blind, 
parallel-arm trial to assess the efficacy of dronedarone 400 mg 
twice daily for the prevention of cardiovascular hospitalization 
or death from any cause in patients with AF/AFL (ATHENA) 
was a placebo controlled multicenter study including 4628 
patients. The primary end point was death or hospitalization 
for a cardiovascular reason. Inclusion criteria were a history 
of paroxysmal or persistent AF and at least one of following 
risk factors: age of minimum 70 years, arterial hypertension 
(with ongoing therapy involving at least two antihypertensive 
drugs of different classes), diabetes mellitus, previous stroke, Clinical Interventions in Aging 2010:5 66
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transient ischemic attack, systemic embolism, minimum left 
atrial diameter of 50 mm or LVEF of 40% or less. At the 
time of enrollment 1176 (25%) of the patients had either 
AF or AFL. A history of NYHA class II or III heart failure 
was present in 979 patients. However, only 179 patients 
(4%) had LVEF  35%. The overall mortality figures were 
lower than expected, so the steering committee changed the 
inclusion criteria to enrich the risk profile of the overall study 
population. With the revised criteria patients aged 75 years 
or older could be included whether or not they had any of the 
specified risk factors. Patients aged 70 years or older could be 
included if they had at least one of the risk factors. Patients 
younger than 70 years could no longer be included. Patients 
included in the study had an intermediate to high risk for 
stroke and other cardiovascular events. In total, 60% received 
oral anticoagulant therapy (OAC) and one-fourth of these 
received both OAC and an antiplatelet agent. Mean follow-
up period was 21 months. Exclusion criteria included per-
manent AF, severe heart failure (NYHA class IV), unstable 
hemodynamic condition, bradycardia, planned major surgery 
and glomerular filtration rate of less than 10 mL per minute. 
The population in ATHENA therefore varied considerably 
from the population in ANDROMEDA as the ATHENA 
patients were all clinically stable and had non-permanent 
AF. In contrast, patients in the ANDROMEDA study were 
hospitalized and the majority did not have AF. Thus, in the 
ATHENA study investigators excluded patients similar to 
those participating in ANDROMEDA, and included only 
patients for whom dronedarone was developed. In ATHENA, 
734 patients (31.9%) in the dronedarone group reached 
the primary end point of either death from any cause or 
hospitalization for cardiovascular reasons vs 917 (39.4%) in 
the placebo group (HR 0.76; 95% CI 0.69 to 0.84; P  0.001), 
respectively. Death from any cause did not differ significantly 
between the two groups, as 116 (5%) in the dronedarone 
group vs 139 (6.0%) in the placebo group died, respectively 
(HR 0.84, 95% CI, 0.66 to 1.08; P = 0.18). Hospitalization 
for cardiovascular reasons occurred in 675 (29.3%) in the 
dronedarone group vs 859 (36.9%) in the placebo group, 
respectively (HR 0.74; 95% CI 0.67 to 0.82; P  0.001). This 
difference in hospitalizations between the two groups was 
mainly caused by a reduction in the number of hospitalizations 
for AF. However, hospitalizations for AF were often related 
to other cardiovascular events (ie, incompensation, stroke 
or myocardial infarction). Secondary endpoints included 
death from cardiovascular causes and any hospitalization 
due to cardiovascular events. Death from cardiovascular 
reasons occurred in 63 (2.7%) in the dronedarone group vs 
90 (3.9%) in the placebo group (HR = 0.71; 95% CI 0.51 
to 0.98; P = 0.03), respectively. Also, there were 26 deaths 
from cardiac arrhythmia (1.1% of patients) in the droneda-
rone group and 48 (2.1%) in the placebo group (HR, 0.55; 
95% CI, 0.34 to 0.88, P = 0.01), respectively. Any hospital-
ization due to any cardiovascular event or death from any 
cause occurred in 1253 (54.5%) cases in the dronedarone 
group vs 1668 (71.7%) in the placebo group (HR 0.76, 95% 
(CI 0.68 to 0.84), P  0.001). Overall, the ATHENA study 
demonstrated that in elderly patients with nonpermanent AF 
and additional risk factors, dronedarone was safe and reduced 
cardiovascular morbidity/mortality.
How does dronedarone influence 
the risk of stroke?
The positive outcome in the ATHENA trial was mainly driven 
by a reduction in cardiovascular hospitalizations. From the 
published data it is difficult to see how many of these events 
were related to an effect on AF, and to see if dronedarone 
has additional effects not previously anticipated.
In a post hoc analysis deaths were categorized into four 
subgroups: cardiac, arrhythmic; cardiac, nonarrhythmic; 
vascular, noncardiac; and nonvascular. Information was then 
gathered from hospital reports, death reports and adverse 
event reports. All incidents of preferred terms for adverse 
effects that contained the word “stroke”, “cerebrovascular 
accident” or “cerebellar hemorrhage” were counted as 
stroke. Strokes that did not lead to hospitalizations or death 
were reported as adverse effects. The total number of strokes 
was 46 (annual event rate of 1.2%) in the dronedarone 
group and 70 (annual event rate of 1.8%) in the placebo 
group, respectively (HR 0.66, CI 0.46 to 0.96, P = 0.027). 
Figure 1 shows the cumulative risk of stroke and the composite 
outcome of stroke, acute coronary syndrome or cardiovascular 
death. Ischemic strokes accounted for 33 (annual event rate 
0.9%) in the dronedarone group and 49 (annual event rate 
1.3%) in the placebo group, respectively (HR 0.68, CI 0.44 
to 1.05, P = 0.08). Hemorrhagic strokes were 6 in both 
groups (annual event rate 0.2; P = 0.99). Subgroup analysis 
to investigate what baseline characteristics were predictive 
of a response to dronedarone in response to stroke showed 
that patients with a CHADS2 score 2 had a significantly 
greater effect of dronedarone than patients with a CHADS2 
score of 1.18
In EURIDIS and ADONIS the overall incidence of 
stroke was 0.3% (n = 4) in the dronedarone vs 0.5% 
(n = 3) in the placebo group. ERATO and DAFNE, 
which were short-term studies, did not report any cases Clinical Interventions in Aging 2010:5 67
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of stroke, and data from DIONYSOS are not available. 
In the ANDROMEDA trial stroke occurred in 4 (1.3%) in 
the dronedarone group and 3 (0.9%) in the placebo group, 
respectively. In total, 54 cases of stroke occurred in 3439 
patients (crude rate 1.6%) receiving dronedarone compared 
to 76 strokes in 3048 patients on placebo (crude rate 2.5%), 
respectively. The information on the overall risk of stroke 
associated with dronedarone originates mainly from the 
ATHENA trial.
The reduction in stroke demonstrated in the ATHENA trial 
may have important clinical implications. This effect has never 
been demonstrated with any other antiarrhythmic drug, but the 
mechanism is uncertain. Suppression of AF is the most obvi-
ous explanation, but the details of the information collected 
during the ATHENA trial do not allow us to conclude 
this. Secondly, patients with AF that persisted during the 
entire study also had a reduction (nonsignificant) in stroke. 
Dronedarone had at least two other effects that could have 
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Figure 1 The cumulative risk of stroke (A) and the composite outcome of stroke, acute coronary syndrome or cardiovascular death (B). reproduced with permission from 
Connolly SJ, Crijns HJ,   Torp-Pedersen C, et al.  Analysis of stroke in   ATHENA:  a placebo-controlled, double-blind, parallel-arm trial to assess the efficacy of dronedarone 400 mg 
BID for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial fibrillation/atrial flutter. Circulation. 2009;120:1174–1180.18 Copyright © 
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resulted in a reduction in stroke. Heart rate is reduced with 
dronedarone and there was a significant reduction in blood 
pressure in the dronedarone group (approximately 3 mmHg 
in both systolic and diastolic blood pressure) compared to the 
placebo group. These changes in blood pressure are modest, 
but may have importance in a group of patients with many risk 
factors for stroke. The most important limitation of the find-
ings of the post hoc analysis of ATHENA is that the reduction 
in stroke was not anticipated and therefore not prespecified, 
but was found retrospectively. The results of the post hoc anal-
ysis do not provide any information on why antiarrhythmic 
drugs might be able to reduce the risk of stroke, but they do 
provide reasons for future trials to investigate if similar results 
can be repeated and what mechanisms lie behind. Until now 
the reasons for pursuing rhythm control in AF have been 
to improve quality of life and reduce symptoms. However, 
if stoke can be prevented this will open a new scenario for 
treatment of patients at higher risk of stroke. In this context 
it is important to note that the effect on stroke was only seen 
in patients with a CHADS2 score 2 (P = 0.03).
Which patients should be treated 
with dronedarone?
The FDA approval of dronedarone suggests that it may be 
used in patients with paroxysmal or persistent AF or AFL 
who are in sinus rhythm or will be cardioverted. Patients 
should have additional risk factors defined as age above 
70 years, diabetes, hypertension, prior stroke, increased size 
of the left atrium or depressed LVEF (40%). These were 
the criteria for the ATHENA population. Contraindications 
to dronedarone are NYHA class IV , or class II or III with 
a recent episode of hospitalization, ie, the ANDROMEDA 
population. This reflects the available data, but physicians 
may speculate if patients for whom rate control is a target 
could be candidates for dronedarone treatment. The avail-
able studies have mainly focused on rhythm control, except 
for the ERATO study that showed a significant reduction in 
heart rate with dronedarone. Whether the beneficial effect of 
dronedarone found in the ATHENA trial can be extrapolated 
to patients with permanent AF is unknown. Thus, dronedarone 
should primarily be used for rhythm control. However, if 
patients develop permanent AF on dronedarone this does not 
imply that treatment necessarily has to be discontinued. The 
observed reduction in rate may be beneficial to the patients.
Conclusion
Dronedarone is developed as an antiarrhythmic drug and 
the EURIDIS/ADONIS studies found that dronedarone 
can decrease the recurrence of AF. In the ATHENA trial it 
was demonstrated that dronedarone may reduce cardiovas-
cular mortality and morbidity. Importantly, in a post hoc 
analysis stroke was observed to be significantly reduced in 
elderly patients with AF. Since AF is a known risk factor 
for stroke, this result may not be surprising, but previous 
studies have not found any decreased risk in patients treated 
with antiarrhythmic drugs compared to patients treated with 
rate-controlling drugs. Thus, dronedarone may be useful for 
treatment of elderly patients with non-permanent AF.
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